First Financial Bankshares reported mixed Q3 2026 results with earnings per share matching estimates but revenue slightly below projections. The bank achieved a record net income of $74.31 million, driven by a wider net interest margin, marking significant growth from the previous year. Despite the revenue shortfall, diluted EPS rose to $0.52 from $0.36 a year ago. The company is also expanding its Texas footprint with a new full-service branch opening in Bee Cave, Austin, signaling strategic growth in the region.
First Financial Bankshares reported its Q3 2026 earnings. For readers following the Financials sector, here is Pluang's market snapshot as of Oct 16, 2026 19:01 WIB: out of 142 priced US Financials stocks, 84 rose and 49 fell. Notable movers include Hut 8 Corp at USD 74.30 with a 1-day change of -2.35%, Truist Financial Corporation at USD 45.51 down 2.28%, and TeraWulf Inc at USD 12.36 down 2.06%.
Whole Lotta Dank, a Canadian cannabis brand platform, has launched its first brand, Dank Pack, debuting with Blueberry BBL available across Alberta. The company is expanding its portfolio with over 20 SKUs under regulatory review and is actively seek...
Nasdaq announced that trading in CN Healthy Food Tech Group Corp.'s common stock and warrants will resume on October 19, 2026, after being halted since October 1, 2025. The resumption marks the end of a year-long trading suspension, allowing investor...
David Solomon, CEO of Goldman Sachs, has been appointed as the new chair of The Business Council, taking over from Brian Cornell, Executive Chair of Target Corporation. This leadership change comes at a critical time as the Council addresses challeng...
SEDA Experts LLC has appointed Noor Ul Islam as Managing Director, enhancing its capabilities in risk management and securities practices. With nearly 30 years of experience at major financial institutions like Citibank and Barclays, Islam brings dee...
The global pharmaceutical market is projected to grow from USD 1.88 trillion in 2026 to USD 3.22 trillion by 2035, expanding at a CAGR of 6.15%. Growth is fueled by advances in biologics, AI-driven drug discovery, specialty drugs, and manufacturing i...
